Metformin in neoadjuvant systemic therapy of breast cancer patients with metabolic syndrome
Background: The aim of this prospective randomized trial was to investigate the influence of metformin on the effectiveness of neoadjuvant systemic therapy in breast cancer patients with metabolic syndrome. Patients and methods: The study included 72 patients (from 31 to 77 years of age) who receive...
Main Authors: | Liubota Roman, Cheshuk Valeriy, Zotov Olexyy, Vereshchako Roman, Anikusko Mykola, Liubota Iryna, Gur'yanov Vitaliy |
---|---|
Format: | Article |
Language: | English |
Published: |
Institute of Oncology, Sremska Kamenica, Serbia
2018-01-01
|
Series: | Archive of Oncology |
Subjects: | |
Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/0354-7310/2018/0354-73101801001L.pdf |
Similar Items
-
Effects of surgeon volume and hospital volume on clinical outcomes of breast cancer patients
by: Pavlushenko Mariia, et al.
Published: (2023-01-01) -
Metformin as an adjuvant option for systemic treatment of breast cancer
by: D.I. Avierin, et al.
Published: (2023-12-01) -
Metformin Therapy and Breast Cancer Incidence in the Ha’il Region
by: Mhdia Osman, et al.
Published: (2023-01-01) -
Metformin increases pathological responses to rectal cancers with neoadjuvant chemoradiotherapy: a systematic review and meta-analysis
by: I-Li Lai, et al.
Published: (2023-07-01) -
Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer
by: Kuo-Chang Wen, et al.
Published: (2020-08-01)